Tsao May N, Sahgal Arjun, Xu Wei, De Salles Antonio, Hayashi Motohiro, Levivier Marc, Ma Lijun, Martinez Roberto, Régis Jean, Ryu Sam, Slotman Ben J, Paddick Ian
Department of Radiation Oncology, University of Toronto, Odette Cancer Centre, Toronto, ON, Canada, M4N 3M5.
Department of Biostatistics, University of Toronto, ON, Canada, M5G 2M9.
J Radiosurg SBRT. 2017;5(1):5-24.
The aim of this systematic review was to develop International Stereotactic Radiosurgery Society (ISRS) consensus guideline statements for vestibular schwannoma.
A systematic review of the literature was performed up to April 2015.
A total of 55 full-text articles were included in the analysis. All studies were retrospective, except for 2 prospective quality of life studies. Five-year tumour control rates with Gamma Knife radiosurgery (RS), single fraction linac RS, or fractionated (either hypofractionated or conventional fractionation) stereotactic radiation therapy (FSRT) were similar at 81-100%. The single fraction RS series (linac or Gamma Knife) with tumour marginal doses between 12 and 14 Gy revealed 5-year tumour control rates of 90-99%, hearing preservation rates of 41-79%, facial nerve preservation rates of 95-100% and trigeminal preservation rates of 79-99%.There were 6 non-randomized studies comparing single fraction RS versus FSRT. There was no statistically significant difference in tumour control; HR=1.66 (95% CI 0.81, 3.42), p =0.17, facial nerve function; HR = 0.67 (95% CI 0.30, 1.49), p =0.33, trigeminal nerve function; HR = 0.80 (95% CI 0.41, 1.56), p =0.51, and hearing preservation; HR = 1.10 (95% CI 0.72, 1.68), p =0.65 comparing single fraction RS with FSRT.Nine quality of life reports yielded conflicting results as to which modality (surgery, observation, or radiation) was associated with better quality of life outcomes.
There are no randomized trials to help guide management of patients with vestibular schwannoma. Within the limitations of the retrospective series, a number of consensus statements were made.
本系统评价旨在制定国际立体定向放射外科协会(ISRS)关于前庭神经鞘瘤的共识指南声明。
截至2015年4月对文献进行了系统评价。
分析共纳入55篇全文文章。除2项前瞻性生活质量研究外,所有研究均为回顾性研究。伽玛刀放射外科(RS)、单次分割直线加速器RS或分次(超分割或常规分割)立体定向放射治疗(FSRT)的5年肿瘤控制率相似,为81%-100%。肿瘤边缘剂量在12至14 Gy之间的单次分割RS系列(直线加速器或伽玛刀)显示5年肿瘤控制率为90%-99%,听力保留率为41%-79%,面神经保留率为95%-100%,三叉神经保留率为79%-99%。有6项非随机研究比较了单次分割RS与FSRT。在肿瘤控制方面无统计学显著差异;风险比(HR)=1.66(95%置信区间0.81,3.42),p =0.17;面神经功能方面,HR = 0.67(95%置信区间0.30,1.49),p =0.33;三叉神经功能方面,HR = 0.80(95%置信区间0.41,1.56),p =0.51;听力保留方面,比较单次分割RS与FSRT时HR = 1.10(95%置信区间0.72,1.68),p =0.65。九份生活质量报告对于哪种治疗方式(手术、观察或放疗)与更好的生活质量结果相关得出了相互矛盾的结果。
尚无随机试验可帮助指导前庭神经鞘瘤患者的管理。在回顾性系列研究的局限性内,制定了一些共识声明。